【摘 要】
：
1.Opportunity.Pharmaceutical markets development have slowed to 2.5%-3.5%; and revenue growth is softening most in those countries where a high portion of drug costs are self-paid,such as the U.S.,Chi
【出 处】
：
中国上海第七届国际新药发明科技年会
论文部分内容阅读
1.Opportunity.Pharmaceutical markets development have slowed to 2.5%-3.5%; and revenue growth is softening most in those countries where a high portion of drug costs are self-paid,such as the U.S.,China,and Brazil.US pharmaceutical sales will decline by 1% to 2% in 2009 (IMS Health); while BRIC countries will grow to 7-8% percent of the global market by 2011.The 7 "pharmerging" markets-China,Brazil,Mexico,Korea,India,Turkey and Russia-show 13-16% growth in 2009.This creates a unique 《pull》 toward the Pharma markets of these countries.Biotech investment financing is at historic low levels,effectively stranding more than 1,000 Biotech programs due to funding limitations.Repositioning by Pharma,along with high 《back pressure》 created by high discovery-stage productivity has enlarged outlicensing portfolios to hundreds of partnerable assets.The development bottleneck creates a unique opportunity for alternative development strategies with experienced and reputable 《development partners》 based on shared risk and joint venture investment models; a model embraced by early innovators,including Lillys Chorus,J&J eRED,Novartis new venture initiatives,and other pioneers.
其他文献
Protein microarray technology has made enormous progress in recent years.It has been successfully applied for the identification,quantification and functional analysis of proteins in basic and applied
The effort to replace chemical ring systems forms a large part of the medicinal chemistry practice.This paper describes effort at GlaxoSmithKline in developing a comprehensive database of drug rings s
An understanding of structural geometry and the nature of intermolecular interactions is often important for the efficient design or selection of drug candidates for synthesis or testing.Therefore eas
The skyrocketing cost for drug development requires pharmaceutical and biotech industry to increase the possibility of success for their drug development candidates in the later stage of their develop
Transmembrane transporters (in short,transporters) move hydrophilic substrates across hydrophobic biological membranes and play key roles in nutrition intake,metabolism,signaling in living cells.There
Purpose:Advanced,castration-resistant prostate cancer,for which there are few treatment options,remains one of the leading causes of cancer death.MicroRNAs (miRNAs) have provided a new opportunity for
MicroRNAs (miRNAs) contains 18-24 nucleotides,which are often linked as clusters transcribed from genomic DNAs.The miR-17~92 is the most extensively studied cluster.This cluster and its paralogs play
Schistosomiasis causes liver and intestinal damage and can be very debilitating.The pairing of a male worm with a female worm residing in the gynaecophoral canal of male plays a critical role in the d
A live cell profiling approach for real-time monitoring and profiling of small molecules compounds will be described.The non-invasive readout allows continuous monitoring of cells inside the wells pro
Up-regulation ofproinflammatory cytokines by activated macrophages (Mψ) has been shown to drive the pathogenesis of several rheumatic diseases including rheumatoid arthritis,chronic plaque psoriasis,a